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CORRESPONDENCE
South Africa’s adoption of the World 
Health Organization’s ‘test and treat’ 
guidelines: Are we too ambitious?
To the Editor: Health minister Dr Aaron Motsoaledi has announced 
that South Africa will adopt the World Health Organization (WHO)’s 
new ‘test and treat’ guidelines from September 2016, enabling all 
patients living with HIV to be eligible for antiretroviral therapy 
(ART).
This radical policy change is evidenced by the Strategic Timing 
Anti-Retroviral Treatment (START) study,[1] a 2011 trial conducted 
in 35 countries with 4 685 participants, half of whom initiated ART 
immediately when diagnosed with HIV and the other half as soon 
as their CD4 count dropped <350 cells/µL. The study indicated a 
beneficial effect of immediate ART for both AIDS-related and non-
AIDS-related events, and also reported no increased rates of adverse 
effects associated with this strategy. This evidence was so compelling 
that the trial was stopped prematurely, as it was unethical to delay 
ART to those not on treatment.
It has been suggested that the ‘test and treat’ guidelines hold the 
potential to eliminate the epidemic by breaking the cycle of HIV 
transmission and reducing ART costs in the long term; however, 
numerous modelling studies have found contradictory evidence to 
the WHO model, which under-estimated the survival time on ART 
and ignored the threat of resistance developing after widespread 
ART use.[2,3] Furthermore, it is not clear how the already overstrained 
healthcare system will deal with a high influx of patients on 
treatment, who would require baseline CD4 count testing as well as 
virological monitoring. A drastic increase in patient turnover could 
result in resources being further strained, especially with regard to 
clinical and laboratory capacity. This may result in the patients most 
at risk of death with comorbidities and low CD4 counts being missed 
by the healthcare system.
It is suggested that before implementing a ‘test and treat’ strategy, 
which may not be sustainable, achieving universal access to treatment 
with gradual increments in CD4 criteria later on may be more 
effective in eliminating the epidemic. However, the policy wheels 
were already in motion from September, and it is now more 
important than ever that clinicians maintain vigilance to diagnose 
HIV-infected patients at a high risk of poor outcomes in the midst of 
an influx of generally healthier HIV-infected patients.
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